Percutaneous BCG Enhances Innate Effector Antitumor Cytotoxicity During Treatment of Bladder Cancer: A Translational Clinical Trial
OncoImmunology - United States
doi 10.1080/2162402x.2019.1614857
Full Text
Open PDFAbstract
Available in full text
Date
May 25, 2019
Authors
Publisher
Informa UK Limited